 David Kao
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 31 | 2023 | 1945 | 4.930 |
Why?
| | Stroke Volume | 16 | 2022 | 504 | 2.120 |
Why?
| | Machine Learning | 5 | 2022 | 316 | 1.830 |
Why?
| | Methadone | 5 | 2023 | 77 | 1.680 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 64 | 1.590 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 287 | 1.570 |
Why?
| | Buprenorphine | 3 | 2023 | 134 | 1.510 |
Why?
| | Cardiomyopathies | 5 | 2022 | 298 | 1.490 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 176 | 1.410 |
Why?
| | Pharmacogenetics | 5 | 2024 | 149 | 1.250 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 279 | 1.210 |
Why?
| | Electronic Health Records | 7 | 2024 | 800 | 1.180 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 24 | 1.060 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2023 | 348 | 1.050 |
Why?
| | Propanolamines | 3 | 2019 | 90 | 0.950 |
Why?
| | Torsades de Pointes | 4 | 2016 | 17 | 0.790 |
Why?
| | Telemedicine | 3 | 2020 | 662 | 0.770 |
Why?
| | Pulmonary Edema | 1 | 2021 | 115 | 0.750 |
Why?
| | Coffee | 1 | 2021 | 10 | 0.740 |
Why?
| | Stroke | 2 | 2021 | 1022 | 0.730 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 53 | 0.710 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 401 | 0.710 |
Why?
| | Humans | 78 | 2024 | 114662 | 0.700 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 286 | 0.690 |
Why?
| | Mobile Applications | 1 | 2021 | 141 | 0.670 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 70 | 0.650 |
Why?
| | Prosthesis Failure | 1 | 2020 | 115 | 0.640 |
Why?
| | Long QT Syndrome | 3 | 2016 | 59 | 0.640 |
Why?
| | Spironolactone | 1 | 2019 | 28 | 0.640 |
Why?
| | Device Removal | 1 | 2020 | 126 | 0.640 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 106 | 0.630 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 38 | 0.630 |
Why?
| | Medical Records | 2 | 2019 | 153 | 0.620 |
Why?
| | Coronary Disease | 1 | 2021 | 348 | 0.620 |
Why?
| | Mortality | 3 | 2019 | 287 | 0.610 |
Why?
| | Periodicals as Topic | 1 | 2020 | 181 | 0.600 |
Why?
| | Artificial Intelligence | 1 | 2019 | 144 | 0.600 |
Why?
| | United States | 19 | 2021 | 12181 | 0.590 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 771 | 0.590 |
Why?
| | Aged | 27 | 2022 | 19069 | 0.580 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 45 | 0.570 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 322 | 0.560 |
Why?
| | Risk Assessment | 7 | 2020 | 2968 | 0.560 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 52 | 0.550 |
Why?
| | Hospital Records | 1 | 2016 | 11 | 0.540 |
Why?
| | Hospitalization | 9 | 2021 | 1751 | 0.530 |
Why?
| | Proteoglycans | 1 | 2017 | 107 | 0.530 |
Why?
| | Female | 43 | 2022 | 59493 | 0.520 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.510 |
Why?
| | Survival | 1 | 2015 | 37 | 0.500 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.500 |
Why?
| | Myocardial Infarction | 3 | 2018 | 927 | 0.500 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 50 | 0.490 |
Why?
| | Retrospective Studies | 19 | 2022 | 12546 | 0.490 |
Why?
| | Research Design | 1 | 2020 | 928 | 0.480 |
Why?
| | Biomedical Research | 1 | 2020 | 585 | 0.480 |
Why?
| | Middle Aged | 25 | 2021 | 26733 | 0.470 |
Why?
| | Registries | 2 | 2020 | 1768 | 0.460 |
Why?
| | Diet | 1 | 2021 | 1080 | 0.440 |
Why?
| | Loperamide | 2 | 2023 | 10 | 0.440 |
Why?
| | Male | 35 | 2022 | 55583 | 0.440 |
Why?
| | United States Food and Drug Administration | 4 | 2016 | 172 | 0.440 |
Why?
| | Myocardium | 3 | 2017 | 913 | 0.440 |
Why?
| | Precision Medicine | 6 | 2024 | 337 | 0.440 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 1879 | 0.430 |
Why?
| | Quality Improvement | 2 | 2020 | 950 | 0.430 |
Why?
| | Muscle Proteins | 1 | 2015 | 210 | 0.430 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 152 | 0.420 |
Why?
| | Adult | 26 | 2022 | 30544 | 0.420 |
Why?
| | Patient Readmission | 1 | 2018 | 610 | 0.410 |
Why?
| | Legislation, Medical | 1 | 2012 | 10 | 0.410 |
Why?
| | Peripartum Period | 4 | 2022 | 9 | 0.410 |
Why?
| | Amiodarone | 1 | 2012 | 23 | 0.410 |
Why?
| | Postoperative Complications | 2 | 2020 | 2128 | 0.390 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 106 | 0.390 |
Why?
| | Catheter Ablation | 1 | 2015 | 288 | 0.390 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 1727 | 0.380 |
Why?
| | Heart Arrest | 4 | 2019 | 292 | 0.380 |
Why?
| | Pyrazines | 2 | 2008 | 71 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2021 | 9088 | 0.370 |
Why?
| | Hospital Mortality | 5 | 2022 | 776 | 0.370 |
Why?
| | Triazoles | 2 | 2008 | 131 | 0.360 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 485 | 0.360 |
Why?
| | Databases, Factual | 5 | 2020 | 1125 | 0.350 |
Why?
| | Transfusion Reaction | 1 | 2011 | 65 | 0.350 |
Why?
| | Patient Transfer | 1 | 2012 | 143 | 0.350 |
Why?
| | Patient Discharge | 2 | 2021 | 772 | 0.350 |
Why?
| | Ventricular Function, Left | 4 | 2022 | 467 | 0.350 |
Why?
| | Insurance, Health | 1 | 2012 | 244 | 0.350 |
Why?
| | Anemia | 1 | 2011 | 143 | 0.330 |
Why?
| | Risk Factors | 8 | 2020 | 8632 | 0.330 |
Why?
| | Genotype | 3 | 2024 | 1760 | 0.320 |
Why?
| | Renal Insufficiency | 1 | 2011 | 137 | 0.320 |
Why?
| | Thiazolidinediones | 1 | 2010 | 142 | 0.320 |
Why?
| | Marketing | 1 | 2008 | 24 | 0.320 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 16 | 0.310 |
Why?
| | Simvastatin | 1 | 2008 | 59 | 0.310 |
Why?
| | Heart Ventricles | 4 | 2017 | 712 | 0.310 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 44 | 0.300 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 45 | 0.300 |
Why?
| | Electrocardiography | 4 | 2019 | 560 | 0.300 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1075 | 0.290 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1177 | 0.290 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 811 | 0.290 |
Why?
| | Drug Industry | 1 | 2008 | 103 | 0.290 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 24 | 0.290 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 250 | 0.290 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2013 | 68 | 0.280 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1815 | 0.280 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 151 | 0.270 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 94 | 0.260 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2319 | 0.260 |
Why?
| | Young Adult | 9 | 2022 | 10466 | 0.250 |
Why?
| | Phenotype | 3 | 2020 | 2796 | 0.250 |
Why?
| | Cause of Death | 2 | 2019 | 361 | 0.250 |
Why?
| | Pregnancy | 6 | 2022 | 5518 | 0.250 |
Why?
| | Ventricular Remodeling | 2 | 2017 | 226 | 0.250 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 637 | 0.240 |
Why?
| | Glucose | 1 | 2010 | 896 | 0.240 |
Why?
| | Pandemics | 3 | 2022 | 1317 | 0.240 |
Why?
| | Incidence | 4 | 2021 | 2313 | 0.240 |
Why?
| | Adolescent | 10 | 2020 | 17841 | 0.240 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6345 | 0.240 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 373 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1214 | 0.230 |
Why?
| | Sex Factors | 3 | 2019 | 1715 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 671 | 0.220 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.220 |
Why?
| | Prognosis | 5 | 2020 | 3329 | 0.210 |
Why?
| | Medicare | 2 | 2020 | 665 | 0.210 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 68 | 0.200 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1012 | 0.200 |
Why?
| | Naltrexone | 1 | 2023 | 83 | 0.200 |
Why?
| | Insulin Resistance | 1 | 2010 | 1072 | 0.200 |
Why?
| | Hypertension | 2 | 2020 | 1056 | 0.190 |
Why?
| | Time Factors | 3 | 2020 | 6115 | 0.190 |
Why?
| | Referral and Consultation | 2 | 2017 | 632 | 0.190 |
Why?
| | Smartphone | 1 | 2021 | 73 | 0.190 |
Why?
| | Red Meat | 1 | 2021 | 12 | 0.180 |
Why?
| | Speech | 1 | 2021 | 68 | 0.180 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 34 | 0.180 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 321 | 0.180 |
Why?
| | Actigraphy | 1 | 2021 | 74 | 0.180 |
Why?
| | Losartan | 1 | 2020 | 9 | 0.180 |
Why?
| | Software | 2 | 2015 | 530 | 0.180 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 21 | 0.180 |
Why?
| | Lisinopril | 1 | 2020 | 13 | 0.180 |
Why?
| | Protective Factors | 1 | 2021 | 87 | 0.180 |
Why?
| | Angioedema | 1 | 2020 | 15 | 0.180 |
Why?
| | American Heart Association | 2 | 2019 | 264 | 0.180 |
Why?
| | Biological Products | 1 | 2023 | 166 | 0.180 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 42 | 0.180 |
Why?
| | Turner Syndrome | 1 | 2021 | 44 | 0.180 |
Why?
| | Data Accuracy | 1 | 2020 | 48 | 0.180 |
Why?
| | California | 2 | 2012 | 353 | 0.180 |
Why?
| | Social Determinants of Health | 1 | 2022 | 135 | 0.170 |
Why?
| | Milk | 1 | 2021 | 124 | 0.170 |
Why?
| | Bionics | 1 | 2019 | 11 | 0.170 |
Why?
| | Editorial Policies | 1 | 2020 | 45 | 0.170 |
Why?
| | Medical Futility | 1 | 2019 | 20 | 0.170 |
Why?
| | Medical Informatics | 1 | 2020 | 90 | 0.170 |
Why?
| | Medical Record Linkage | 1 | 2020 | 53 | 0.170 |
Why?
| | Drug Overdose | 1 | 2023 | 292 | 0.160 |
Why?
| | Echocardiography | 2 | 2019 | 553 | 0.160 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 106 | 0.160 |
Why?
| | Cohort Studies | 3 | 2021 | 4895 | 0.160 |
Why?
| | Prescription Drugs | 1 | 2020 | 116 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2021 | 239 | 0.160 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 228 | 0.160 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 30 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1842 | 0.160 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 41 | 0.160 |
Why?
| | Tobacco Use | 1 | 2019 | 60 | 0.150 |
Why?
| | Child Health Services | 1 | 2020 | 176 | 0.150 |
Why?
| | Prospective Studies | 4 | 2021 | 6219 | 0.150 |
Why?
| | Cluster Analysis | 1 | 2019 | 455 | 0.150 |
Why?
| | Computer Graphics | 2 | 2015 | 41 | 0.150 |
Why?
| | Length of Stay | 3 | 2021 | 962 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4411 | 0.150 |
Why?
| | Advisory Committees | 1 | 2019 | 208 | 0.150 |
Why?
| | Florida | 1 | 2018 | 73 | 0.150 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 8 | 0.150 |
Why?
| | Forecasting | 1 | 2019 | 330 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2019 | 154 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2020 | 411 | 0.140 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 429 | 0.140 |
Why?
| | Population Surveillance | 1 | 2020 | 392 | 0.140 |
Why?
| | Patient Participation | 1 | 2020 | 359 | 0.140 |
Why?
| | Nursing Assessment | 1 | 2017 | 49 | 0.140 |
Why?
| | Consensus | 1 | 2019 | 537 | 0.140 |
Why?
| | Pressure Ulcer | 1 | 2017 | 31 | 0.140 |
Why?
| | Cardiology | 1 | 2019 | 259 | 0.140 |
Why?
| | Heart Diseases | 1 | 2020 | 331 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 103 | 0.130 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.130 |
Why?
| | Genetic Markers | 1 | 2017 | 320 | 0.130 |
Why?
| | Computational Biology | 2 | 2017 | 530 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2017 | 206 | 0.130 |
Why?
| | Oxycodone | 1 | 2016 | 44 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1518 | 0.130 |
Why?
| | Sex Distribution | 1 | 2016 | 337 | 0.130 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 5 | 0.130 |
Why?
| | Rheumatic Fever | 1 | 2015 | 7 | 0.130 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 29 | 0.120 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 17 | 0.120 |
Why?
| | Marijuana Use | 1 | 2018 | 167 | 0.120 |
Why?
| | Naloxone | 1 | 2016 | 97 | 0.120 |
Why?
| | Mothers | 1 | 2020 | 651 | 0.120 |
Why?
| | Angiotensin II | 1 | 2015 | 87 | 0.120 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 22 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 39 | 0.120 |
Why?
| | United Kingdom | 1 | 2015 | 226 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 444 | 0.120 |
Why?
| | Heart Rate | 2 | 2022 | 709 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 740 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 2894 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1448 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2015 | 116 | 0.110 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 136 | 0.110 |
Why?
| | Chronic Disease | 2 | 2020 | 1578 | 0.110 |
Why?
| | MicroRNAs | 2 | 2017 | 600 | 0.110 |
Why?
| | Gene Expression | 2 | 2017 | 1421 | 0.110 |
Why?
| | Cholesterol | 1 | 2015 | 367 | 0.110 |
Why?
| | Down-Regulation | 1 | 2015 | 594 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 607 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2017 | 2552 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 358 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 449 | 0.100 |
Why?
| | Federal Government | 1 | 2012 | 26 | 0.100 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 98 | 0.100 |
Why?
| | Drug Resistance | 1 | 2012 | 158 | 0.100 |
Why?
| | Colorado | 4 | 2024 | 4099 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2085 | 0.100 |
Why?
| | Area Under Curve | 1 | 2012 | 274 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1796 | 0.100 |
Why?
| | Patient Safety | 1 | 2015 | 277 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3408 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 913 | 0.090 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 102 | 0.090 |
Why?
| | Survival Rate | 1 | 2015 | 1644 | 0.090 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 337 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 207 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 900 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2012 | 329 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2012 | 1660 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1177 | 0.090 |
Why?
| | Managed Care Programs | 2 | 2022 | 133 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 203 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2017 | 833 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2538 | 0.080 |
Why?
| | Primary Health Care | 1 | 2019 | 1512 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1430 | 0.080 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 33 | 0.080 |
Why?
| | Drug Approval | 1 | 2008 | 78 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 590 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2010 | 302 | 0.070 |
Why?
| | Animals | 3 | 2023 | 31699 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 1841 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 140 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 413 | 0.070 |
Why?
| | Zimbabwe | 2 | 2017 | 42 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 238 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3003 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 951 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1620 | 0.060 |
Why?
| | Depression | 2 | 2022 | 1134 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4408 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 120 | 0.060 |
Why?
| | Mandible | 1 | 2004 | 62 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 36 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 718 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 35 | 0.050 |
Why?
| | Algorithms | 3 | 2020 | 1468 | 0.050 |
Why?
| | Child | 5 | 2020 | 18412 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 37 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 79 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 112 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 3 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 168 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 222 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2022 | 195 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 11 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 22 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 36 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1879 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 430 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 280 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 442 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 27 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 635 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 37 | 0.040 |
Why?
| | Bias | 1 | 2020 | 179 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2469 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 186 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 1947 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 228 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 304 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 380 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 544 | 0.040 |
Why?
| | Focus Groups | 1 | 2019 | 383 | 0.040 |
Why?
| | Neoplasms | 1 | 2010 | 2097 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1078 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 76 | 0.030 |
Why?
| | Pharmacovigilance | 1 | 2016 | 14 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 462 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 106 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 313 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 168 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 30 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 102 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 287 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 81 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1538 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 100 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2763 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1036 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 979 | 0.030 |
Why?
| | Mass Screening | 2 | 2013 | 1004 | 0.030 |
Why?
| | Infant | 2 | 2015 | 7961 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 562 | 0.020 |
Why?
| | Child, Preschool | 2 | 2015 | 9114 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 41 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 4512 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 89 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 931 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 76 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 179 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 822 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2362 | 0.020 |
Why?
| | Mice | 1 | 2023 | 14863 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 198 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 634 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 94 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 371 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 663 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 425 | 0.020 |
Why?
| | Hospitals, University | 1 | 2005 | 172 | 0.010 |
Why?
| | Dentists | 1 | 2004 | 19 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1262 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 59 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 53 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 224 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 145 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 21 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1226 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 432 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 562 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1168 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 893 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 1982 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2785 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 772 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|